Bristol-Myers Squibb Company (BMY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bristol-Myers Squibb Company stock (BMY) is currently trading at $58.94. Bristol-Myers Squibb Company PE ratio is 17.03. Bristol-Myers Squibb Company PS ratio (Price-to-Sales) is 2.49. Analyst consensus price target for BMY is $62.72. WallStSmart rates BMY as Hold.
- BMY PE ratio analysis and historical PE chart
- BMY PS ratio (Price-to-Sales) history and trend
- BMY intrinsic value — DCF, Graham Number, EPV models
- BMY stock price prediction 2025 2026 2027 2028 2029 2030
- BMY fair value vs current price
- BMY insider transactions and insider buying
- Is BMY undervalued or overvalued?
- Bristol-Myers Squibb Company financial analysis — revenue, earnings, cash flow
- BMY Piotroski F-Score and Altman Z-Score
- BMY analyst price target and Smart Rating
Bristol-Myers Squibb Company
📊 No data available
Try selecting a different time range
BMY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Bristol-Myers Squibb Company (BMY)
BMY trades at a significant discount to its Graham intrinsic value of $161.93, offering a 63% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Bristol-Myers Squibb Company (BMY) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, operating margin. Concerns around price/book and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Bristol-Myers Squibb Company (BMY) Key Strengths (5)
Every $100 of shareholder equity generates $40 in profit
Earnings per share surging 1392.00% year-over-year
83.11% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $28 kept per $100 revenue
Supporting Valuation Data
Bristol-Myers Squibb Company (BMY) Areas to Watch (5)
Very expensive at 6.3x book value
Revenue growing slowly at 1.30% annually
Paying a premium for growth, expensive relative to earnings expansion
Revenue is fairly priced at 2.49x sales
Decent profitability, keeps $15 per $100 revenue
Bristol-Myers Squibb Company (BMY) Detailed Analysis Report
Overall Assessment
This company scores 64/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, EPS Growth, Institutional Own.. Profitability is solid with Return on Equity at 40.40%, Operating Margin at 28.20%. Growth metrics are encouraging with EPS Growth at 1392.00%.
The Bear Case
The primary concerns are Price/Book, Revenue Growth, PEG Ratio. Some valuation metrics including PEG Ratio (2.26), Price/Sales (2.49), Price/Book (6.34) suggest expensive pricing. Growth concerns include Revenue Growth at 1.30%, which may limit upside. Profitability pressure is visible in Profit Margin at 14.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 40.40% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 1.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, EPS Growth) and negatives (Price/Book, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BMY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BMY's Price-to-Sales ratio of 2.49x trades 34% below its historical average of 3.79x (24th percentile). The current valuation is 65% below its historical high of 7.17x set in Apr 2016, and 42% above its historical low of 1.75x in Feb 2009.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bristol-Myers Squibb Company (BMY) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Bristol-Myers Squibb Company is a strong growth company balancing expansion with improving profitability. Revenue reached 48.2B with 130% growth year-over-year. Profit margins of 14.6% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 130% YoY, reaching 48.2B. This pace significantly outperforms most DRUG MANUFACTURERS - GENERAL peers.
ROE of 4040.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Debt-to-equity ratio of 2.55 is elevated. High leverage amplifies both gains and losses and increases financial risk.
What to Watch Next
Margin expansion: can Bristol-Myers Squibb Company push profit margins above 15% as the business scales?
Growth sustainability: can Bristol-Myers Squibb Company maintain 130%+ revenue growth, or will competition slow it down?
Dividend sustainability with a current yield of 4.3%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 47.1B is significantly higher than cash (10.2B). Monitor refinancing risk.
Bottom Line
Bristol-Myers Squibb Company offers an attractive blend of growth (130% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Bristol-Myers Squibb Company(BMY)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.